Filtered By:
Procedure: PET Scan
Nutrition: Vitamins

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 63 results found since Jan 2013.

C-Reactive Protein Predicts Hematoma Growth in Intracerebral Hemorrhage Clinical Sciences
Conclusions— CRP>10 mg/L is independently predictive of EHG and ENW, both of which are associated with increased mortality. Inflammation may be important in contributing to EHG and warrants further investigation.
Source: Stroke - December 23, 2013 Category: Neurology Authors: Di Napoli, M., Parry-Jones, A. R., Smith, C. J., Hopkins, S. J., Slevin, M., Masotti, L., Campi, V., Singh, P., Papa, F., Popa-Wagner, A., Tudorica, V., Godoy, D. A. Tags: Cerebrovascular disease/stroke, Acute Cerebral Hemorrhage, Intracerebral Hemorrhage, Pathology of Stroke Clinical Sciences Source Type: research

Vitamin K Antagonist–associated Intracerebral Hemorrhage: Lessons from a Devastating Disease in the Dawn of the New Oral Anticoagulants
Conclusions: VKA-associated ICH presents in a particularly vulnerable population and has a poor prognosis that may be reliably predicted by several clinicoradiologic features.
Source: Journal of Stroke and Cerebrovascular Diseases - August 19, 2013 Category: Neurology Authors: Marta Suárez-Pinilla, Ángeles Fernández-Rodríguez, Lorena Benavente-Fernández, Sergio Calleja-Puerta Tags: Original Articles Source Type: research

Horizon scanning: Phase II study of betrixaban vs. warfarin in patients with atrial fibrillation (Explore-Xa)
Source: Eur Heart J Area: News Betrixaban is an investigational once daily oral factor Xa inhibitor mostly excreted unchanged in the bile and with low (17%) renal excretion. The phase II study assessed its safety and tolerability at three different doses compared with warfarin in 508 patients with AF and more than one risk factor for stroke.   The patients had mean CHADS2 score of 2.2 and 87% had previously received vitamin K antagonist therapy. They were randomised to betrixaban 40, 60, or 80 mg once daily (n= 127 each dose) or unblinded warfarin, adjusted to an INR of 2.0-3.0 (n= 127). The primary outcome was m...
Source: NeLM - Cardiovascular Medicine - March 14, 2013 Category: Cardiology Source Type: news